NCT06126406View on ClinicalTrials.gov

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Gastric CancerColon CancerRectal CancerBreast CancerLung CancerEsophagus CancerCholangiocarcinomaPancreas Cancer
Interventions
BIOLOGICAL

CEA-targeted CAR-T cells

Administration method: intravenous infusion Subjects will receive conditioning therapy by ludarabine and Cyclophosphamide before cell infusion.

BIOLOGICAL

CEA-targeted CAR-T cells

Administration method: intraperitoneal injection Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Wannan Medical College, Wuhu

All Listed Sponsors
collaborator

First Affiliated Hospital of Wannan Medical College

OTHER

lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY